EiRx, BioMerieux Pen PGx Alliance to Validate Each Other's Dx, Rx Biomarkers
EiRx Therapeutics and BioMérieux last week said they plan to validate the diagnostic and therapeutic potential of their candidate tumor markers.
Terms of the alliance call for BioMérieux to see if proteins in EiRx's biomarker panel can become components in new diagnostics for colorectal cancer. Meanwhile, EiRx will use its siRNA-driven platform to test BioMérieux's colorectal biomarker panel as targets for new drug therapies.
During the evaluation phase of the collaboration, which will last up to 18 months, EiRx has granted BioMérieux an exclusive option to license and "exploit" diagnostic applications of its biomarker intellectual property.
Similarly, BioMérieux has granted EiRx an exclusive option to license and "exploit" therapeutic applications of its own IP, and said it will develop companion diagnostics for any drug candidates developed by EiRx against targets proposed by BioMérieux.
Financial details of the agreement were not disclosed.
European Patent Office Reinstates ABI's PCR Thermal Cycler IP
Applied Biosystems this week said that the Technical Board of Appeal of the European Patent Office has reinstated its patent covering real-time PCR thermal cycler technology.
The ruling overturns a December 2004 decision by the Opposition Division to revoke the patent for "alleged lack of novelty," ABI said. The case will be returned to the Opposition Division for review of other issues.
The patent is European Patent No. 872562.
Additional details were not disclosed.
Decode to Raise $30M in Stock Offering
Decode Genetics plans to raise $30 million in a common stock offering to new and existing institutional investors, the company said last week.
Decode said it will sell 6 million shares at $5 apiece. The shares traded at $5.2376 mid-day on Wednesday. The company expects net proceeds after expenses to be approximately $27.8 million.
Decode said it expects to close the transaction on or about July 18.
Illumina Pens SNP-Genotyping Deal With J&J's R&D Group
Illumina last week said it will develop custom SNP content for a multi-sample Sentrix BeadChip for Johnson & Johnson Pharmaceutical Research & Development.
The BeadChip platform enables researchers to analyze 12 samples and as many as 60,000 SNPs per sample on a single BeadChip. Illumina expects to use its Infinium assay to genotype "thousands" of samples provided by J&JPRD.
Financial details were not disclosed.
Agendia Receives CE Mark for CupPrint
Agendia's CupPrint microarray service has acquired Medical Device registration at the Dutch Healthcare Inspectorate, the company said last week.
Agendia received CE registration for MammaPrint in 2005.
CupPrint is a test for cancer of unknown primary patients.
"With the CE registration of both its products and the ISO 17025 accreditation of its laboratory services, Agendia ... [can] market its products and ... provide a legal basis for its use in clinical practice," Laura van 't Veer, COO of Agendia, said in a statement.
Beckman Coulter Pays Roche $27.5M to License RT-PCR Technology for IVD Use
Beckman Coulter this week said it has acquired an in vitro diagnostics product license to all of Roche's real-time PCR patents and pending patent applications.
In exchange, Beckman Coulter will pay Roche a one-time license fee of $27.5 million and will also pay royalties on sales of all licensed products.
Beckman recently settled a patent-infringement suit with ABI that enabled it to license thermal cycler technology for RT-PCR instrumentation. The Roche license, meantime, "gives our company the intellectual property required to meet the molecular testing needs of routine labs for an automated, fully integrated system," Beckman CEO Scott Garrett said in a statement.
Affy, Caliper, Luminex Added Back to Nasdaq Biotech Index
The Nasdaq exchange said last week that it has reinstated several genomics companies that it dropped from the Nasdaq Biotechnology Index in May.
Affymetrix, Caliper, and Luminex are among five firms added to the index following an interim review.
Nasdaq said in a statement that the "sole purpose" of the review was "to include some companies that were removed from the index during the May semi-annual re-ranking due to sector classification assigned by the Industry Classification Benchmark."
In May, Accelrys, Affymetrix, Caliper Life Sciences, and Luminex were among nine firms dropped from the index due to a change in their ICB classification.
"As a result of ICB's recent sector evaluation, five securities will be added back into the Index as their sector classification has been changed to biotechnology or pharmaceutical," Nasdaq said on Friday. "In addition to qualifying for this sector, companies being added back met all other continued eligibility criteria."
The change will become effective on July 24.